DRUG · Mapped RxNorm record
Taletrectinib
Normalized identity: taletrectinib View linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
NCT06564324
Study summary
ClinicalTrials.govA Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE3
Loading study purpose, treatment groups and outcomes…
View the complete registry record, eligibility and contacts at ClinicalTrials.gov
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Crizotinib
Normalized identity: crizotinib View linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Advertisement
Conditions
Non Small Cell Lung Cancerunresolved
Interventions
TaletrectinibDRUG · verified · RxNorm: taletrectinib
CrizotinibDRUG · verified · RxNorm: crizotinib
Sponsors & collaborators
Nuvation Bio Inc.lead sponsor
Mapped research locations
ShanghaiShanghai Municipality, China3BeijingBeijing Municipality, China2GuangzhouGuangdong, China2HangzhouZhejiang, China2ZhengzhouHenan, China2NanjingJiangsu, China1ChangshaHunan, China1WuhanHubei, China1ChengduSichuan, China1TianjinTianjin Municipality, China1ShenyangLiaoning, China1ChongqingChongqing Municipality, China1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06564324 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.